Does IL23R rs11209026 GG increase susceptibility to mucosal inflammation?

The rs11209026 polymorphism in the IL23R gene is one of the most significant genetic determinants of susceptibility to inflammatory bowel disease (IBD). The GG genotype represents the ancestral, "wild-type" state of the receptor, while the A allele (Arg381Gln) is a relatively rare but highly protective variant that actively dampens inflammatory signaling.

Clinical evidence and risk

The association between the IL23R rs11209026 GG genotype and mucosal inflammation is backed by extensive genomic data.

• Disease Susceptibility: Large-scale meta-analyses, including studies with over 20,000 subjects, consistently identify the G allele as the risk-conferring variant. Individuals with the GG genotype have an approximately 2.4 to 4.0 times higher risk of developing Crohn’s disease compared to those carrying at least one protective A allele (OR ≈ 0.41 for the A allele).
• Population Prevalence: In Caucasian populations, the protective A allele frequency is low (approximately 5% to 7%). Consequently, the majority of the population carries the GG genotype, maintaining a baseline genetic susceptibility to IL-23-mediated inflammation.

Mechanistic explanations

The increased susceptibility in GG carriers is driven by the absence of a "molecular brake" present in A allele carriers.

• Receptor Function: The rs11209026 G allele encodes the Arg381 variant of the IL-23 receptor. This "wild-type" receptor maintains full functional capacity, characterized by efficient protein stability and robust cell-surface expression.
• Signal Transduction: Upon stimulation by the cytokine IL-23, the GG genotype allows for unrestrained activation of the JAK2/STAT3 signaling pathway. In contrast, the protective A allele (Gln381) results in a hypomorphic (reduced function) receptor that exhibits significantly diminished STAT3 phosphorylation.
• Th17 Response: Because the IL-23/STAT3 axis is critical for the survival and expansion of Th17 cells, GG carriers produce higher levels of pro-inflammatory cytokines, such as IL-17 and IL-22. This unchecked Th17 response is a primary driver of the chronic mucosal damage seen in Crohn's disease and ulcerative colitis.

Bottom line

The claim is strongly supported. The rs11209026 GG genotype facilitates mucosal inflammation by maintaining the full signaling potential of the IL-23/Th17 axis. In contrast, the protective A allele acts as a loss-of-function variant that actively restrains this inflammatory pathway.